Pinus roxburghii alleviates bone porosity and loss in postmenopausal osteoporosis by regulating estrogen, calcium homeostasis and receptor activator of nuclear factor-κB, osteoprotegerin, cathepsin bone markers

J Pharm Pharmacol. 2021 Jun 8;73(7):901-915. doi: 10.1093/jpp/rgaa014.

Abstract

Objectives: The study was aimed to evaluate the potential of hydroalcoholic extract of Pinus roxburghii (PRE) stem bark in post-menopausal osteoporosis and its underlying mechanisms.

Methods: In silico docking of the markers was done using AutoDock version 4.2. for molecular targets: receptor activator of nuclear factor-κB (RANK), osteoprotegerin (OPG) and Cathepsin. Female Wistar rats of bodyweight 200-250 g were employed and surgical ovariectomy (OVX) was performed. PRE was administered at a dose of 100 and 200 mg/kg whereas standard drug, raloxifene given at 1 mg/kg orally for eight weeks.

Key findings: PRE (20 and 40 µg/mL) significantly increased the cellular proliferation in osteoblastic UMR cell lines 11.58 and 15.09% respectively. Eight weeks after surgical removal of ovaries, a significant bone porosity was confirmed by modulation in bone breaking strength of tibia, lumber, and femur; bone mineral density (BMD), calcium, phosphorus, hydroxyproline levels in OVX group. Treatment with PRE 100 and 200 mg/kg significantly restored the bone loss. Real-time polymerase chain reaction (RT-PCR) analysis of molecular markers RANK, OPG and cathepsin and histology also confirmed the attenuation of bone loss. The quantification of quercetin, gallic acid, caffeic acid, catechin, tannic acid and ascorbic acid was done by high-performance liquid chromatography (HPLC) and high performance thin layer chromatography.

Conclusions: P. roxburghii produced anti-osteoporotic effect possibly due to estrogenic modulation, and improved bone remodeling.

Keywords: Pinus roxburghii; in silico; in-vitro; RT-PCR; post-menopausal osteoporosis.

MeSH terms

  • Animals
  • Bone Density / drug effects
  • Bone Density Conservation Agents / pharmacology*
  • Bone Remodeling / drug effects
  • Cathepsins / metabolism
  • Cell Proliferation / drug effects
  • Estrogens / metabolism*
  • Female
  • Humans
  • Osteoblasts / drug effects
  • Osteoblasts / physiology
  • Osteoporosis, Postmenopausal* / drug therapy
  • Osteoporosis, Postmenopausal* / metabolism
  • Osteoporosis, Postmenopausal* / pathology
  • Osteoprotegerin / metabolism
  • Pinus*
  • Plant Extracts
  • Porosity / drug effects*
  • Raloxifene Hydrochloride / pharmacology
  • Rats
  • Receptor Activator of Nuclear Factor-kappa B / metabolism*
  • Treatment Outcome

Substances

  • Bone Density Conservation Agents
  • Estrogens
  • Osteoprotegerin
  • Plant Extracts
  • Receptor Activator of Nuclear Factor-kappa B
  • Raloxifene Hydrochloride
  • Cathepsins